Channel Therapeutics Corp. Files Q1 2025 10-Q
Ticker: PTHS · Form: 10-Q · Filed: 2025-05-13T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Channel Therapeutics filed its Q1 2025 10-Q. All systems go.
AI Summary
Channel Therapeutics Corp. filed its 10-Q for the period ending March 31, 2025. The company, formerly Chromocell Therapeutics Corp, is incorporated in Nevada and operates in the biological products sector. Its principal executive offices are located at 685 US Highway One, North Brunswick, NJ.
Why It Matters
This filing provides a quarterly update on Channel Therapeutics Corp.'s financial health and operational status, crucial for investors and stakeholders to assess the company's performance.
Risk Assessment
Risk Level: low — The filing is a routine quarterly report and does not contain immediate, high-impact news.
Key Numbers
- 0.32 — Common Stock Price (Reported value for the period)
- 0.55 — Common Stock Price (Reported value for the period)
Key Players & Entities
- Channel Therapeutics Corp. (company) — Filer of the 10-Q
- Chromocell Therapeutics Corp (company) — Former name of Channel Therapeutics Corp.
- 20250331 (date) — End of reporting period
- 20250513 (date) — Filing date
- 685 US Highway One, North Brunswick, NJ (location) — Business and mailing address
FAQ
What is the company's primary business activity?
Channel Therapeutics Corp. is in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code [2836].
When was the company formerly known as Chromocell Therapeutics Corp.?
The date of the name change from Chromocell Therapeutics Corp. to Channel Therapeutics Corp. was March 23, 2022.
What is the fiscal year end for Channel Therapeutics Corp.?
The fiscal year end for Channel Therapeutics Corp. is December 31.
What is the SEC file number for Channel Therapeutics Corp.?
The SEC file number is 001-41964.
What are the reported stock prices for the period?
The filing reports a common stock price of $0.32 and $0.55 for the period.
From the Filing
0001753926-25-000790.txt : 20250513 0001753926-25-000790.hdr.sgml : 20250513 20250513163108 ACCESSION NUMBER: 0001753926-25-000790 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250513 DATE AS OF CHANGE: 20250513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Channel Therapeutics Corp CENTRAL INDEX KEY: 0001919246 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 863335449 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41964 FILM NUMBER: 25940664 BUSINESS ADDRESS: STREET 1: 685 US HIGHWAY ONE CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 BUSINESS PHONE: 9176446313 MAIL ADDRESS: STREET 1: 685 US HIGHWAY ONE CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 FORMER COMPANY: FORMER CONFORMED NAME: Chromocell Therapeutics Corp DATE OF NAME CHANGE: 20220323 10-Q 1 g084808_10q.htm 10-Q false 2025 --12-31 Q1 0001919246 0.32 0.32 0.55 0.55 1967611 131317 P9Y0M29D P9Y4M24D P8Y10M14D P9Y9M3D P10Y P9Y3M26D P9Y2M12D P9Y9M3D P9Y4M24D P8Y10M14D P10Y P9Y3M26D P9Y2M12D 0001919246 2025-01-01 2025-03-31 0001919246 2025-05-13 0001919246 2025-03-31 0001919246 2024-12-31 0001919246 us-gaap:SeriesAPreferredStockMember 2025-03-31 0001919246 us-gaap:SeriesAPreferredStockMember 2024-12-31 0001919246 us-gaap:SeriesCPreferredStockMember 2025-03-31 0001919246 us-gaap:SeriesCPreferredStockMember 2024-12-31 0001919246 2024-01-01 2024-03-31 0001919246 chro:PreferredASharesMember 2023-12-31 0001919246 chro:PreferredCSharesMember 2023-12-31 0001919246 us-gaap:CommonStockMember 2023-12-31 0001919246 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001919246 us-gaap:RetainedEarningsMember 2023-12-31 0001919246 2023-12-31 0001919246 chro:PreferredASharesMember 2024-12-31 0001919246 chro:PreferredCSharesMember 2024-12-31 0001919246 us-gaap:CommonStockMember 2024-12-31 0001919246 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001919246 us-gaap:RetainedEarningsMember 2024-12-31 0001919246 chro:PreferredASharesMember 2024-01-01 2024-03-31 0001919246 chro:PreferredCSharesMember 2024-01-01 2024-03-31 0001919246 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001919246 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001919246 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001919246 chro:PreferredASharesMember 2025-01-01 2025-03-31 0001919246 chro:PreferredCSharesMember 2025-01-01 2025-03-31 0001919246 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001919246 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001919246 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001919246 chro:PreferredASharesMember 2024-03-31 0001919246 chro:PreferredCSharesMember 2024-03-31 0001919246 us-gaap:CommonStockMember 2024-03-31 0001919246 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001919246 us-gaap:RetainedEarningsMember 2024-03-31 0001919246 2024-03-31 0001919246 chro:PreferredASharesMember 2025-03-31 0001919246 chro:PreferredCSharesMember 2025-03-31 0001919246 us-gaap:CommonStockMember 2025-03-31 0001919246 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001919246 us-gaap:RetainedEarningsMember 2025-03-31 0001919246 2024-02-19 2024-02-21 0001919246 2024-02-21 0001919246 us-gaap:IPOMember 2024-02-19 2024-02-21 0001919246 us-gaap:IPOMember 2025-01-01 2025-03-31 0001919246 chro:ConsultantMember 2025-01-01 2025-03-31 0001919246 chro:ConsultantMember 2024-01-01 2024-03-31 0001919246 chro:LabGasMember 2025-01-01 2025-03-31 0001919246 chro:LabGasMember 2024-01-01 2024-03-31 0001919246 chro:LabCellStorageMember 2025-01-01 2025-03-31 0001919246 chro:LabCellStorageMember 2024-01-01 2024-03-31 0001919246 chro:ChemistryManufacturingAndControlsMember 2025-01-01 2025-03-31 0001919246 chro:ChemistryManufacturingAndControlsMember 2024-01-01 2024-03-31 0001919246 chro:IPServicesMember 2025-01-01 2025-03-31 0001919246 chro:IPServicesMember 2024-01-0